{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:20:08Z","timestamp":1782984008841,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.repc.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:32:45Z","timestamp":1719599565000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-vitamin K versus vitamin K antagonist oral anticoagulants in surgical mitral valve repair or bioprosthetic valve replacement in the first three months after surgery"],"prefix":"10.1016","volume":"43","author":[{"given":"Hugo","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cust\u00f3dio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Baptista Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lamares Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sousa Uva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2024.02.013_bib0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(09)60780-7","article-title":"Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends","volume":"374","author":"Sun","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2024.02.013_bib0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jtcvs.2008.08.015","article-title":"Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database","volume":"137","author":"Brown","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Dur\u00e3es","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.repc.2024.02.013_bib0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.repc.2023.01.001","article-title":"Direct oral anticoagulants and surgical bioprosthetic valves: state of the art","volume":"42","author":"Magro","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2024.02.013_bib0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ehjcvp\/pvx028","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"4","author":"Caldeira","year":"2018","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"10.1016\/j.repc.2024.02.013_bib0170","article-title":"Dabigatran vs. warfarin in patients with mechanical heart valves","volume":"26","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.repc.2024.02.013_bib0285","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.repc.2024.02.013_bib0180","first-page":"72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.02.013_bib0185","first-page":"524","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"75","author":"Vahanian","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.repc.2024.02.013_bib0190","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jtcvs.2009.10.064","article-title":"Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?","volume":"139","author":"ElBardissi","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0195","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jtcvs.2004.11.028","article-title":"Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?","volume":"129","author":"Sundt","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0200","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","article-title":"High risk of thromboemboli early after bioprosthetic cardiac valve replacement","volume":"25","author":"Heras","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2024.02.013_bib0205","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/icvts\/ivab363","article-title":"Are NOACs as safe and efficient as VKA regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?","volume":"34","author":"Magro","year":"2022","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ejcts\/ezad110","article-title":"Direct oral anticoagulants versus vitamin K antagonists in the first 3 months after bioprosthetic valve replacement: a systematic review and meta-analysis","volume":"63","author":"Eikelboom","year":"2023","journal-title":"Eur J Cardio-thoracic Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/ejcts\/ezad113","article-title":"Is it the time for direct oral anticoagulants in bioprosthetic heart valves?","volume":"63","author":"Saade","year":"2023","journal-title":"Eur J Cardio-thoracic Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0220","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.02.013_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0230","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2024.02.013_bib0235","doi-asserted-by":"crossref","first-page":"A19","DOI":"10.1093\/eurheartj\/suab151","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease","volume":"24","author":"Fanaroff","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.repc.2024.02.013_bib0240","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a meta-analysis","volume":"2401","author":"Yokoyama","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.repc.2024.02.013_bib0245","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.repc.2024.02.013_bib0250","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation \u2013 the ROCKET-AF trial","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.02.013_bib0255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/VHRM.S121661","article-title":"Evaluation of bleeding in patients receiving direct oral anticoagulants","volume":"13","author":"Hellenbart","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.repc.2024.02.013_bib0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"169","author":"Granger","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.repc.2024.02.013_bib0265","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.jcin.2019.10.017","article-title":"Switching oral anticoagulant therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"12","author":"Franchi","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.repc.2024.02.013_bib0270","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2024.02.013_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcvm.2021.702780","article-title":"Antithrombotic treatment after surgical and transcatheter heart valve repair and replacement","volume":"8","author":"Verstraete","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2024.02.013_bib0280","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.hroo.2022.09.020","article-title":"Management of atrial fibrillation in rheumatic heart disease","volume":"3","author":"Shenthar","year":"2022","journal-title":"Heart Rhythm O2"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255124001884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255124001884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T10:30:14Z","timestamp":1724927414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255124001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0870255124001884"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2024.02.013","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-vitamin K versus vitamin K antagonist oral anticoagulants in surgical mitral valve repair or bioprosthetic valve replacement in the first three months after surgery","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}